arXiv subjects

Xianbin Ye

Publications and source records attributed to Xianbin Ye.

10 recordsLinked to original sources

arXiv2026

End-to-End Reverse Screening Identifies Protein Targets of Small Molecules Using HelixFold3

Identifying protein targets for small molecules, or reverse screening, is essential for understanding drug action, guiding compound repurposing, predicting off-target effects, and elucidating the molecular mechanisms of bioactive compounds. Despite its critical role, reverse screening remains challenging because accurately capturing interactions between a small molecule and structurally diverse proteins is inherently complex, and conventional step-wise workflows often propagate errors across decoupled steps such as target structure modeling, pocket identification, docking, and scoring. Here, we present an end-to-end reverse screening strategy leveraging HelixFold3, a high-accuracy biomolecular structure prediction model akin to AlphaFold3, which simultaneously models the folding of proteins from a protein library and the docking of small-molecule ligands within a unified framework. We validate this approach on a diverse and representative set of approximately one hundred small molecules. Compared with conventional reverse docking, our method improves screening accuracy and demonstrates enhanced structural fidelity, binding-site precision, and target prioritization. By systematically linking small molecules to their protein targets, this framework establishes a scalable and straightforward platform for dissecting molecular mechanisms, exploring off-target interactions, and supporting rational drug discovery.

q-bio.BM↗

arXiv2025

HelixVS: Deep Learning-Enhanced Structure-Based Platform for Screening and Design

Drug discovery through virtual screening (VS) has become a popular strategy for identifying hits against protein targets. Alongside VS, molecular design further expands accessible chemical space. Together, these approaches have the potential to reduce the cost and time needed for manual selection and wet-laboratory experiments, thereby accelerating drug discovery pipelines. Improving the cost-effectiveness of virtual screening is a significant challenge, aiming to explore larger compound libraries while maintaining lower screening costs. Here, we present HelixVS, a structure-based VS platform enhanced by deep learning models. HelixVS integrates a precise deep learning-based pose-scoring model and a pose-screening module into a multi-stage VS process, enabling more effective screening of active compounds. Compared to classic molecular docking tools like Vina, HelixVS demonstrated significantly improved screening performance across nearly a hundred targets, achieving an average 2.6-fold higher enrichment factor (EF) and more than 10 times faster screening speed. We applied HelixVS in four drug development pipelines, targeting both traditional competitive drug-binding pockets and novel protein-protein interaction interfaces. Wet-lab validations across these pipelines consistently identified active compounds, with over 10% of the molecules tested in wet labs demonstrating activity at uM or even nM levels. This demonstrates the ability of HelixVS to identify high-affinity ligands for various targets and pockets.In addition, the HelixVS platform has been extended with HelixVS-Syn, which enables design of novel compounds from reference scaffolds. These designed molecules are seamlessly integrated into the HelixVS screening workflow, allowing researchers to explore both existing chemical libraries and novel chemical space with high affinity, synthetic accessibility, and structural novelty.

q-bio.BM↗

arXiv2025

BioScore: A Foundational Scoring Function For Diverse Biomolecular Complexes

Structural assessment of biomolecular complexes is vital for translating molecular models into functional insights, shaping our understanding of biology and aiding drug discovery. However, current structure-based scoring functions often lack generalizability across diverse biomolecular systems. We present BioScore, a foundational scoring function that addresses key challenges -- data sparsity, cross-system representation, and task compatibility -- through a dual-scale geometric graph learning framework with tailored modules for structure assessment and affinity prediction. BioScore supports a wide range of tasks, including affinity prediction, conformation ranking, and structure-based virtual screening. Evaluated on 16 benchmarks spanning proteins, nucleic acids, small molecules, and carbohydrates, BioScore consistently outperforms or matches 70 traditional and deep learning methods. Our newly proposed PPI Benchmark further enables comprehensive evaluation of protein-protein complex scoring. BioScore demonstrates broad applicability: (1) pretraining on mixed-structure data boosts protein-protein affinity prediction by up to 40% and antigen-antibody binding correlation by over 90%; (2) cross-system generalizability enables zero- and few-shot prediction with up to 71% correlation gain; and (3) its unified representation captures chemically challenging systems such as cyclic peptides, improving affinity prediction by over 60%. BioScore establishes a robust and generalizable framework for structural assessment across complex biomolecular landscapes.

physics.chem-ph↗

arXiv2025

Reshaping Biomolecular Structure Prediction through Strategic Conformational Exploration with HelixFold-S1

Generating large ensembles of candidate conformations is standard for improving biomolecular structure prediction. Yet aimless sampling is inefficient and costly, producing many redundant conformations with limited diversity, particularly for complex multimeric assemblies. Here, we present HelixFold-S1, a guided planning approach specifically designed to enhance the structural prediction of biomolecular complexes by strategically targeting the most informative regions of conformational space to produce accurate conformations. For each complex, predicted inter-chain contact probabilities serve as a blueprint of the conformational space, guiding computational effort toward higher-probability, low-redundancy contacts that constrain structure generation. Across diverse biomolecular complex benchmarks, HelixFold-S1 achieves markedly higher structural accuracy than traditional unguided methods while reducing sampling requirements by an order of magnitude. Predicted contact probabilities also provide a rough indicator of prediction difficulty and sampling utility. These results demonstrate that guided planning reshapes conformational exploration and enables more efficient and accurate structural inference.

q-bio.BM↗

arXiv2024

Technical Report of HelixFold3 for Biomolecular Structure Prediction

The AlphaFold series has transformed protein structure prediction with remarkable accuracy, often matching experimental methods. AlphaFold2, AlphaFold-Multimer, and the latest AlphaFold3 represent significant strides in predicting single protein chains, protein complexes, and biomolecular structures. While AlphaFold2 and AlphaFold-Multimer are open-sourced, facilitating rapid and reliable predictions, AlphaFold3 remains partially accessible through a limited online server and has not been open-sourced, restricting further development. To address these challenges, the PaddleHelix team is developing HelixFold3, aiming to replicate AlphaFold3's capabilities. Leveraging insights from previous models and extensive datasets, HelixFold3 achieves accuracy comparable to AlphaFold3 in predicting the structures of the conventional ligands, nucleic acids, and proteins. The initial release of HelixFold3 is available as open source on GitHub for academic research, promising to advance biomolecular research and accelerate discoveries. The latest version will be continuously updated on the HelixFold3 web server, providing both interactive visualization and API access.

q-bio.BM↗

arXiv2024

Pre-Training on Large-Scale Generated Docking Conformations with HelixDock to Unlock the Potential of Protein-ligand Structure Prediction Models

Protein-ligand structure prediction is an essential task in drug discovery, predicting the binding interactions between small molecules (ligands) and target proteins (receptors). Recent advances have incorporated deep learning techniques to improve the accuracy of protein-ligand structure prediction. Nevertheless, the experimental validation of docking conformations remains costly, it raises concerns regarding the generalizability of these deep learning-based methods due to the limited training data. In this work, we show that by pre-training on a large-scale docking conformation generated by traditional physics-based docking tools and then fine-tuning with a limited set of experimentally validated receptor-ligand complexes, we can obtain a protein-ligand structure prediction model with outstanding performance. Specifically, this process involved the generation of 100 million docking conformations for protein-ligand pairings, an endeavor consuming roughly 1 million CPU core days. The proposed model, HelixDock, aims to acquire the physical knowledge encapsulated by the physics-based docking tools during the pre-training phase. HelixDock has been rigorously benchmarked against both physics-based and deep learning-based baselines, demonstrating its exceptional precision and robust transferability in predicting binding confirmation. In addition, our investigation reveals the scaling laws governing pre-trained protein-ligand structure prediction models, indicating a consistent enhancement in performance with increases in model parameters and the volume of pre-training data. Moreover, we applied HelixDock to several drug discovery-related tasks to validate its practical utility. HelixDock demonstrates outstanding capabilities on both cross-docking and structure-based virtual screening benchmarks.

cs.LG↗

arXiv2022

CandidateDrug4Cancer: An Open Molecular Graph Learning Benchmark on Drug Discovery for Cancer

Anti-cancer drug discoveries have been serendipitous, we sought to present the Open Molecular Graph Learning Benchmark, named CandidateDrug4Cancer, a challenging and realistic benchmark dataset to facilitate scalable, robust, and reproducible graph machine learning research for anti-cancer drug discovery. CandidateDrug4Cancer dataset encompasses multiple most-mentioned 29 targets for cancer, covering 54869 cancer-related drug molecules which are ranged from pre-clinical, clinical and FDA-approved. Besides building the datasets, we also perform benchmark experiments with effective Drug Target Interaction (DTI) prediction baselines using descriptors and expressive graph neural networks. Experimental results suggest that CandidateDrug4Cancer presents significant challenges for learning molecular graphs and targets in practical application, indicating opportunities for future researches on developing candidate drugs for treating cancers.

cs.LG↗

arXiv2022

PASH at TREC 2021 Deep Learning Track: Generative Enhanced Model for Multi-stage Ranking

This paper describes the PASH participation in TREC 2021 Deep Learning Track. In the recall stage, we adopt a scheme combining sparse and dense retrieval method. In the multi-stage ranking phase, point-wise and pair-wise ranking strategies are used one after another based on model continual pre-trained on general knowledge and document-level data. Compared to TREC 2020 Deep Learning Track, we have additionally introduced the generative model T5 to further enhance the performance.

cs.IR↗

arXiv2021

Docking-based Virtual Screening with Multi-Task Learning

Machine learning shows great potential in virtual screening for drug discovery. Current efforts on accelerating docking-based virtual screening do not consider using existing data of other previously developed targets. To make use of the knowledge of the other targets and take advantage of the existing data, in this work, we apply multi-task learning to the problem of docking-based virtual screening. With two large docking datasets, the results of extensive experiments show that multi-task learning can achieve better performances on docking score prediction. By learning knowledge across multiple targets, the model trained by multi-task learning shows a better ability to adapt to a new target. Additional empirical study shows that other problems in drug discovery, such as the experimental drug-target affinity prediction, may also benefit from multi-task learning. Our results demonstrate that multi-task learning is a promising machine learning approach for docking-based virtual screening and accelerating the process of drug discovery.

cs.LG↗

arXiv2021

Winner Team Mia at TextVQA Challenge 2021: Vision-and-Language Representation Learning with Pre-trained Sequence-to-Sequence Model

TextVQA requires models to read and reason about text in images to answer questions about them. Specifically, models need to incorporate a new modality of text present in the images and reason over it to answer TextVQA questions. In this challenge, we use generative model T5 for TextVQA task. Based on pre-trained checkpoint T5-3B from HuggingFace repository, two other pre-training tasks including masked language modeling(MLM) and relative position prediction(RPP) are designed to better align object feature and scene text. In the stage of pre-training, encoder is dedicate to handle the fusion among multiple modalities: question text, object text labels, scene text labels, object visual features, scene visual features. After that decoder generates the text sequence step-by-step, cross entropy loss is required by default. We use a large-scale scene text dataset in pre-training and then fine-tune the T5-3B with the TextVQA dataset only.

cs.CV↗